白细胞介素1及其受体拮抗剂阿那白滞素在川崎病中的研究进展

Research progress on interleukin-1 and its receptor antagonist anakinra in Kawasaki disease

川崎病是不同遗传背景和环境因素作用下在心血管组织涉及的炎症应答,可引起心肌炎、血管炎和慢性心血管重塑,最终导致不可逆转的心脏后遗症。研究发现白细胞介素1(IL-1)促炎途径在急性川崎病患儿中被上调,并在川崎病动物模型中起到关键作用,提示IL-1是川崎病发病的重要介质,阻断IL-1通路的靶向治疗可能是一种有效的治疗手段。目前IL-1受体拮抗剂(IL-1Ra)阿那白滞素已成功用于静脉注射用丙种球蛋白抵抗和危重川崎病患儿的临床治疗,但因临床资料的缺乏,IL-1在川崎病人群中的作用机制和IL-1Ra在川崎病中的应用还需要深入探索。

Kawasaki disease(KD)is an inflammatory response in cardiovascular tissue under the action of different genetic backgrounds and environmental factors,which can cause myocarditis,vasculitis,and lead to chronic cardiovascular remodeling,resulting in irreversible cardiac sequelae.It has been found that interleukin-1(IL-1)pro-inflammatory pathway is up-regulated in children with acute KD and plays a key role in KD animal models,suggesting that IL-1 may be an important mediator in the pathogenesis of KD,and the targeted therapy of blocking IL-1 pathway may be an effective treatment.Anakinra,an IL-1 receptor antagonist(IL-1 Ra),has been successfully used in the clinical treatment of severe,intravenous immunoglobulin resistance KD patients.However,due to the lack of clinical data,the mechanism of IL-1 in KD and the application of IL-1 Ra in KD need further explore.